Clinical trial
Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell…
NCT00290355 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00290355 |
|---|---|
| Title | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery |
| Official title | A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-Small Cell |
| Intervention type | Biological |
| Interventions | GSK 249553 vaccine, Placebo |
| Enrollment | 182 |
| Start date | May 28, 2002 |
| Primary completion | Jul 19, 2011 |
| Completion | Jul 19, 2011 |
| First posted | Feb 13, 2006 |
| Last update posted | Jan 2, 2020 |
| Countries | Belgium, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Lithuania, Netherlands, Norway, Poland and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: